Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q6)Jun 30, 2025 | (FY)Dec 31, 2024 | (Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | (FY)Dec 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash flow from operating activities | ||||||||||
| Earning before tax | ---- | -1.63%-53.35M | ---- | 32.45%-52.49M | ---- | 81.84%-77.72M | ---- | -5,969.57%-428.01M | ---- | -94.75%7.29M |
| Profit adjustment | ||||||||||
| Interest (income) - adjustment | ---- | 14.53%-100K | ---- | 18.75%-117K | ---- | 11.11%-144K | ---- | 59.40%-162K | ---- | 44.74%-399K |
| Impairment and provisions: | ---- | 103.34%47.28M | ---- | -56.80%23.25M | ---- | -85.57%53.83M | ---- | 30,087.30%373.12M | ---- | --1.24M |
| -Impairment of trade receivables (reversal) | ---- | ---- | ---- | ---- | ---- | --419K | ---- | ---- | ---- | ---- |
| -Other impairments and provisions | ---- | 103.34%47.28M | ---- | -56.46%23.25M | ---- | -85.69%53.41M | ---- | 30,087.30%373.12M | ---- | --1.24M |
| Revaluation surplus: | ---- | -90.78%80K | ---- | -50.74%868K | ---- | -95.06%1.76M | ---- | 340.37%35.7M | ---- | 100.02%8.11M |
| -Fair value of investment properties (increase) | ---- | -78.95%80K | ---- | -59.49%380K | ---- | -97.33%938K | ---- | 234.49%35.18M | ---- | 160.09%10.52M |
| -Other fair value changes | ---- | ---- | ---- | -40.78%488K | ---- | 58.77%824K | ---- | 121.53%519K | ---- | -26,888.89%-2.41M |
| Asset sale loss (gain): | ---- | ---15.66M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---31K |
| -Loss (gain) from sale of subsidiary company | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---31K |
| -Loss (gain) on sale of property, machinery and equipment | ---- | ---15.66M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Depreciation and amortization: | ---- | -25.26%1.44M | ---- | 14.08%1.93M | ---- | 0.30%1.69M | ---- | -17.72%1.69M | ---- | 15.64%2.05M |
| Financial expense | ---- | 61.75%3.14M | ---- | 114.84%1.94M | ---- | 12.31%903K | ---- | -3.13%804K | ---- | -24.61%830K |
| Special items | ---- | ---9K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Operating profit before the change of operating capital | ---- | 30.23%-17.18M | ---- | -25.14%-24.62M | ---- | -16.66%-19.68M | ---- | -188.38%-16.87M | ---- | -86.85%19.08M |
| Change of operating capital | ||||||||||
| Inventory (increase) decrease | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 200.00%22.74M |
| Developing property (increase)decrease | ---- | 106.69%2.33M | ---- | -4.72%-34.75M | ---- | 71.26%-33.19M | ---- | -318.04%-115.48M | ---- | -89.51%52.96M |
| Accounts payable increase (decrease) | ---- | 7.46%-17.45M | ---- | -474.93%-18.86M | ---- | -94.23%5.03M | ---- | 342.43%87.17M | ---- | -234.84%-35.96M |
| prepayments (increase)decrease | ---- | 722.95%9.04M | ---- | -115.34%-1.45M | ---- | 155.69%9.46M | ---- | -47.67%-16.99M | ---- | 89.30%-11.5M |
| Financial assets at fair value (increase)decrease | ---- | ---- | ---- | 353.72%3.9M | ---- | -38.57%860K | ---- | 134.07%1.4M | ---- | ---4.11M |
| Special items for working capital changes | ---- | -97.07%2.53M | ---- | 98.98%86.47M | ---- | 349.23%43.46M | ---- | 90.39%-17.44M | ---- | 64.51%-181.47M |
| Cash from business operations | -141.20%-27.54M | -294.10%-20.73M | -144.59%-11.42M | 79.77%10.68M | 244.52%25.6M | 107.60%5.94M | 63.07%-17.71M | 43.44%-78.2M | 65.80%-47.96M | -493.75%-138.25M |
| China income tax paid | 137,200.00%2.74M | 99.91%-3K | 99.43%-2K | -174.32%-3.33M | 62.88%-350K | 88.33%-1.22M | 35.59%-943K | -156.61%-10.41M | 40.20%-1.46M | 88.25%-4.06M |
| Net cash from operations | -117.14%-24.79M | -382.17%-20.74M | -145.22%-11.42M | 55.47%7.35M | 235.34%25.25M | 105.33%4.73M | 62.25%-18.66M | 37.73%-88.61M | 65.36%-49.43M | -24,467.12%-142.3M |
| Cash flow from investment activities | ||||||||||
| Interest received - investment | -58.62%24K | -14.53%100K | 7.41%58K | -18.75%117K | 80.00%54K | -11.11%144K | -14.29%30K | -59.40%162K | 2.94%35K | -22.52%399K |
| Loan receivable (increase) decrease | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --0 | --0 | ---- |
| Decrease in deposits (increase) | 569.32%12.09M | 119.33%6.06M | 108.29%1.81M | -379.51%-31.34M | -526.04%-21.78M | -193.03%-6.54M | -172.28%-3.48M | -66.01%7.03M | -72.99%4.81M | 46.90%20.67M |
| Sale of fixed assets | ---- | --30.54M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Purchase of fixed assets | ---- | ---49K | ---- | ---- | ---- | 94.64%-6K | ---- | -433.33%-112K | ---70K | ---21K |
| Sale of subsidiaries | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --18K |
| Recovery of cash from investments | ---- | ---- | ---- | ---- | ---- | -93.29%1.66M | 20,675.00%1.66M | --24.76M | --8K | ---- |
| Net cash from investment operations | 549.79%12.11M | 217.38%36.65M | 108.58%1.86M | -559.29%-31.22M | -1,115.78%-21.73M | -114.88%-4.74M | -137.34%-1.79M | 51.11%31.84M | -73.22%4.79M | 46.22%21.07M |
| Net cash before financing | -32.73%-12.68M | 166.65%15.91M | -371.04%-9.55M | -265,177.78%-23.88M | 117.24%3.53M | 99.98%-9K | 54.20%-20.44M | 53.17%-56.77M | 64.24%-44.64M | -908.61%-121.24M |
| Cash flow from financing activities | ||||||||||
| New borrowing | ---- | ---- | ---- | 5.39%30.52M | ---- | -70.55%28.96M | -72.99%17.54M | -31.89%98.33M | -26.82%64.92M | 646.80%144.36M |
| Refund | ---297K | -70.76%-21.25M | ---- | 64.79%-12.44M | 69.36%-5.07M | 53.25%-35.34M | 72.14%-16.56M | -9.60%-75.59M | -8,796.56%-59.43M | -111.58%-68.96M |
| Issuing shares | -13.03%5.69M | --8.05M | --6.55M | ---- | ---- | ---- | ---- | ---- | ---- | --60.59M |
| Interest paid - financing | 70.71%-488K | -71.71%-3.03M | -205.13%-1.67M | -99.10%-1.76M | -41.45%-546K | -13.30%-886K | -149.03%-386K | -1.43%-782K | 58.33%-155K | 26.08%-771K |
| Issuance expenses and redemption of securities expenses | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---450K |
| Net cash from financing operations | 8.93%4.47M | -211.92%-16.89M | 168.74%4.1M | 282.26%15.1M | -5,069.17%-5.96M | -139.46%-8.28M | -97.53%120K | -84.28%20.99M | -94.43%4.85M | 2,973.98%133.55M |
| Effect of rate | -84.81%53K | 40.44%-430K | 125.18%349K | 77.31%-722K | -310.06%-1.39M | -2,166.23%-3.18M | 21.76%-338K | 107.56%154K | -8,740.00%-432K | -368.16%-2.04M |
| Net Cash | -50.61%-8.22M | 88.83%-981K | -123.75%-5.46M | -5.90%-8.78M | 88.00%-2.44M | 76.83%-8.29M | 48.92%-20.32M | -390.45%-35.78M | -5.18%-39.79M | 19.07%12.32M |
| Begining period cash | -8.20%15.8M | -35.57%17.21M | -35.57%17.21M | -30.05%26.71M | -30.05%26.71M | -48.27%38.18M | -48.27%38.18M | 16.18%73.81M | 16.18%73.81M | 21.19%63.53M |
| Cash at the end | -36.92%7.63M | -8.20%15.8M | -47.12%12.1M | -35.57%17.21M | 30.62%22.89M | -30.05%26.71M | -47.83%17.52M | -48.27%38.18M | 30.68%33.59M | 16.18%73.81M |
| Cash balance analysis | ||||||||||
| Bank deposits | -43.68%21.07M | -15.46%33.16M | 29.61%37.42M | 452.95%39.23M | 614.23%28.87M | --7.09M | --4.04M | ---- | ---- | ---- |
| Cash and cash equivalent balance | -43.68%21.07M | -15.46%33.16M | 29.61%37.42M | 452.95%39.23M | 614.23%28.87M | --7.09M | --4.04M | ---- | ---- | ---- |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
| Audit Opinions | -- | -- | -- | -- | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion |
| Auditor | -- | Changqing (Hong Kong) Certified Public Accountants Limited | -- | Evergreen (Hong Kong) Certified Public Accountants Limited | -- | Evergreen (Hong Kong) Certified Public Accountants Limited | -- | Changqing (Hong Kong) Certified Public Accountants Limited | -- | Deloitte Touche Tohmatsu CPA LLP |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.